1. 3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. (September 2015) Authors: Varga, A.; Camidge, D.R.; Sequist, L.V.; Wakelee, H.; Ou, S.H.; Goldman, J.W.; Papadimitrakopoulou, V.; Gadgeel, S.; Mekhail, T.; Oxnard, G.R.; Socinski, M.; Solomon, B.; Yu, H.; Matheny, S.; Despain, D.; Soria, J.C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S598 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test. (September 2015) Authors: Gadgeel, S.; Soria, J.C.; Goldman, J.W.; Wakelee, H.; Camidge, D.R.; Yu, H.; Varga, A.; Solomon, B.; Oxnard, G.R.; Ou, S.H.; Papadimitrakopoulou, V.; Liu, S.V.; Reckamp, K.; Spira, A.; Piotrowska, Z.; Despain, D.; Karlovich, C.; Yurasov, S.; Sequist, L.V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S628 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3104 Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M. (September 2015) Authors: Solomon, B.; Wakelee, H.; Sequist, L.V.; Gadgeel, S.; Soria, J.C.; Goldman, J.W.; Yu, H.; Camidge, D.R.; Papadimitrakopoulou, V.; Matheny, S.; Despain, D.; Besse, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S636 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. (September 2015) Authors: Soria, J.C.; Goldman, J.W.; Wakelee, H.; Gadgeel, S.; Camidge, D.R.; Solomon, B.; Yu, H.; Oxnard, G.R.; Ou, S.H.; Papadimitrakopoulou, V.; Perol, M.; Reckamp, K.; Varga, A.; Dziadziuszko, R.; Chouaid, C.; Cortot, A.; Do, P.; Moro-Sibilot, D.; Poudenx, M.; Sequist, L.V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S637 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. (December 2022) Authors: Jänne, P.A.; Smit, E.F.; de Marinis, F.; Laskin, J.; Gomez, M. Domine; Gadgeel, S.; Garassino, M.C.; Lu, S.; Spira, A.S.; Kang, V.; Roshan, S.; Yan, X.; Felip, E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. (December 2016) Authors: Gainor, J.; Dardaei, L.; Yoda, S.; Friboulet, L.; Leischler, I.; Katayama, R.; Dagogo-Jack, I.; Gadgeel, S.; Schultz, K.; Singh, M.; Chin, E.; Parks, M.; Lee, D.; DiCecca, R.H.; Lockerman, E.; Huynh, T.; Logan, J.; Benes, C.H.; Engelman, J.A.; Shaw, A. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗